Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Fate Therapeutics strengthens its iPSC Patent Platform

Secures US Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells

 

The (USPTO) United States Patent and Trademark Office has granted Fate Therapeutics a patent covering the novel stem cell modulator commonly known as Thiazovivin.  US Patent No# 8,044,201 entitled “Stem Cell Cultures” claims Thiazovivin, a small molecule Rho-associated kinase (NASDAQ:ROCK) inhibitor, as well as compositions and cell culture media comprising Thiazovivin.

The Bottom Line: Thiazovivin is crucial to the efficient generation of human induced pluripotent stem cells (iPSCs), and the survival of human embryonic stem cells (hESCs), in culture.  Fate Therapeutics holds an exclusive license from The Scripps Research Institute (NASDAQ:TSRI) to the patent in all commercial fields. Thiazovivin, in combination with other small molecules, dramatically improves the reprogramming of human fibroblasts by 200-fold as compared to non-chemically enhanced methods of iPSC generation (Lin, T., et al, Nature Methods 6, 805 – 808 (2009)), and Thiazovivin promotes the survival of hESCs after single-cell dissociation (Xu, Y., et al, PNAS 107(18): 8129-8134).  Thiazovivin is believed to be a critical factor in maintaining the stem cell niche during conditions that might otherwise be detrimental to cell viability.